Agilent Technologies Inc vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? Agilent Technologies Inc trades at $148.72 (market cap $42.00B), while Consumer Discretionary Select Sector SPDR Fund trades at $119.22. The key difference: Agilent Technologies Inc pays a 0.69% dividend while Consumer Discretionary Select Sector SPDR Fund pays none, and Agilent Technologies Inc is trading nearer its 52-week high, Consumer Discretionary Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| A | XLY | |
|---|---|---|
Market Cap | $42.00B | — |
Sector | Health | — |
52-Week High | $157.20 | $124.52 |
52-Week Low | $110.24 | $105.64 |
Enterprise Value | $43.55B | — |
Dividend Yield | 0.69% | — |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
XLY trades at $119.86, up 1.47% with strong bullish technical momentum indicated by moving averages. Analyst consensus is unanimously positive with 100% buy ratings. The consumer discretionary ETF shows resilience amid economic uncertainty, with recent news highlighting its potential as a 'sleeper ETF' for Q3 2026. Technical indicators show overbought conditions on short-term RSI but strong trend momentum on ADX readings.
XLY presents a bullish case with strong technical momentum and unanimous analyst support, though current RSI levels suggest potential near-term consolidation. The ETF's performance hinges on consumer discretionary spending trends amid evolving inflation dynamics. Key risks include consumer confidence erosion and broader economic pressures affecting discretionary purchases.
Trailing returns across standard periods
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →